PARP1 and neoplasm: Since PARP1 inhibition has already been evaluated in numerous different adult-onset tumor types, a variety of potential biomarkers of DNA repair currently exist [i.e., γ-H2AX, poly(ADP-ribose)] and could be incorporated for evaluation in future pediatric trials (Wang and Weaver, 2011).